



a leading *integrated technologies and services* business, enabling the delivery of genomic medicine

Results for the year ended  
31 March 2022 (“FY 22”)

**27 July 2022**



# Disclaimer

**THIS INFORMATION IS CONFIDENTIAL AND IT IS BEING SUPPLIED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE COPIED, REPRODUCED, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. THIS PRESENTATION IS NOT FOR DISTRIBUTION IN THE UNITED STATES, THE REPUBLIC OF SOUTH AFRICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.**

These presentation slides (the "Slides"), the information communicated during any delivery of the Slides (howsoever delivered), including but not limited to any information communicated in any question and answer session and any document or material distributed at or in connection with the Slides (together the "Information") has been prepared by Yourgene Health plc (the "Company", and such term shall also be deemed to include any subsidiaries of the Company) for the sole use at a presentation (the "Presentation") relating to the annual results of the Company for the year ended 31 March 2022. The Information is provided on a confidential basis and is personal to the recipient. The Information does not contain or constitute or form part of an admission document or prospectus nor does the Information contain, constitute, or form part of any offer or invitation to purchase or subscribe for any securities of the Company, or contain or constitute or form part of any solicitation of any offer to purchase or subscribe for any securities of the Company. The Information should not be relied on in connection or a decision to purchase or subscribe for any securities or act as any inducement to enter into any contract or investment decision in relation thereto. The Information does not constitute a recommendation or advice by the Company, Cairn Financial Advisors LLP ("Cairn") as the company's nominated advisor or their respective shareholders, directors, officers, partners, employees, agents, affiliates, representatives or advisors ("Affiliates") regarding any decision to sell or purchase securities in the Company. Accordingly, the Information is being supplied to you solely for your information only. If you are considering engaging in any investment activity, you should seek appropriate independent advice and make your own assessment. The communication of the Information to you should not be taken as any form of commitment on the part of the Company to proceed with any transaction and the Company reserves its right to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company, Cairn or their respective Affiliates be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. The Information is strictly private and confidential and contains material non-public information. The Information may not, without the consent of Cairn and the Company, be reproduced, disseminated, distributed or otherwise disclosed to any other person or published, in whole or in part, for any purpose. No reliance may be placed, for any purpose whatsoever, on the Information or the completeness or accuracy of the Information. No responsibility is accepted, and to the fullest extent permitted by law or regulation, no representation, warranty or other assurance is made or given, in either case, expressly or impliedly, by or on behalf of the Company, Singers Capital Markets, Stifel, or their respective Affiliates or any other person as to the accuracy, completeness, fairness or reasonableness of the Information or any opinions contained therein. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the Information or in connection with it or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to, or in connection with, the Information. The Information does not purport to contain all of the information that may be required to evaluate the Company and may be in preliminary or draft form. The Information is subject to updating, completion, revision, verification and amendment, and such information may change materially. Neither Cairn nor the Company nor their respective Affiliates are under any obligation to verify, update or keep current the Information. The Information may contain forward-looking statements, which relate, inter alia, to the Company's proposed strategy, plans and objectives. Forward-looking statements are sometimes identified by the use of terminology such as "believes", "expects", "may", "will", "could", "should", "shall", "risk", "intends", "estimates", "aims", "plans", "predicts", "continues", "assumes", "positions" or "anticipates" or the negatives thereof, other variations thereon or comparable terminology. By their very nature, such forward-looking information requires the Company to make assumptions that may or may not materialise. Such forward-looking statements may be price sensitive and involve known and unknown risks, uncertainties and other important factors beyond the control of the Company that could cause the actual performance or achievements of the Company to be materially different from such forward-looking statements. Past performance of the Company cannot be relied upon as a guide to future performance. Accordingly, you should not rely on any forward-looking statements and neither the Company nor Cairn nor their respective Affiliates accept any obligation to disseminate any updates or revisions to such forward-looking statements or any other statements in the Information. No statement in the Information is intended as a profit forecast or a profit estimate and no statement in the Information should be interpreted to mean that earnings per share for the current or future financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-looking statements. The Information contains certain financial information which is subject to rounding or approximation. The Information may also contain management estimates. Such estimates have been made in good faith and represent the genuine belief of applicable members of management. Those management members believe that such estimates are founded on reasonable grounds. However, by their nature, estimates may not be correct or complete. Accordingly, no representation or warranty (express or implied) is given that such estimates are correct or complete, and no representation or warranty (express or implied) is given that such estimates are so founded. The Company, Cairn and their Affiliates do not undertake any obligation to correct or complete any estimate whether as a result of becoming aware of information (new or otherwise), future events or otherwise. The Information may contain certain material information that is confidential, price-sensitive and which has not been publicly disclosed. By your receipt of this Presentation, you recognise and accept that some or all of the information in this Presentation may be "inside information" as defined in Article 7 of the Market Abuse Regulation (Regulation 596/2014) ("MAR") and section 56 of the Criminal Justice Act 1993 ("CJA"). You recognise and accept that such information is being provided to you by the Company pursuant to Article 17(8) of MAR and Disclosure Guidance and Transparency Rule 2.5.7G(2) and you confirm, warrant and undertake that you will not: (i) deal in securities that are price-affected securities (as defined in the CJA) in relation to the inside information or encourage another person to deal in price-affected securities or disclose the information except as permitted by the CJA or before the inside information is made public; (ii) deal or attempt to deal in a financial instrument to which MAR applies on the basis of the inside information; (iii) disclose the inside information to another person other than in the proper course of the exercise of your employment, profession or duties; or (iv) engage in behaviour based on any inside information which would breach MAR. The Information is only directed at, persons who are: (a) outside of the United States; (b) in member states of the European Economic Area other than the United Kingdom and who are "qualified investors" within the meaning of Article 2(1)(e) of the Prospectus Directive (as defined below); and (c) in the United Kingdom and are qualified investors and also (i) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (ii) high net worth entities falling within falling within Articles 49(2)(a) to (d) of the Order; or (iii) other persons to whom it can otherwise lawfully be distributed (each a "Relevant Person"). If you have received the Information and you are not a Relevant Person, you must return it (to the extent technologically feasible) to Stifel or the Company immediately. The Information should not be distributed, published, reproduced or otherwise made available in whole or in part by its recipients to any other person or in any other country, locality, state or other jurisdiction where such distribution, publication, availability or use may lead to a breach of any legal or regulatory requirement and, in particular the Slides may not be taken or transmitted or distributed, directly or indirectly, into the United States, or to persons with an address in Australia, the Republic of South Africa, Japan or Canada. It is a condition of you attending the Presentation or receiving the Information that you agree to be bound by the foregoing limitations and restrictions and, in particular, you will be taken to have further represented, warranted and undertaken that: (i) you have read and agree to comply with the contents of this disclaimer; (ii) you are a Relevant Person and you will observe the foregoing provisions, limitations and conditions; (iii) you will keep the Information confidential and take reasonable steps to preserve such confidentiality; and (iv) following the Presentation, you will not at any time have any discussion, correspondence or contact concerning the Information with any of the directors or employees of the Company or its subsidiaries nor with any of their suppliers or customers, or any governmental or regulatory body without the prior written consent of the Company.



# Presenting Team



**Lyn Rees, CEO**


- Joined Yourgene in July 2018 as CEO
- 18 years with BBI Group, CEO for nine years
- Expertise in executing organic and acquisitive growth initiatives including product diversification and international commercialisation
- Completed and integrated seven acquisitions during his tenure at BBI Group, four at Yourgene



**Barry Hextall, CFO**

- Joined Yourgene in June 2015 as CFO
- Significant experience in medical device, instrumentation and diagnostic sectors, including with Immunodiagnostic Systems plc, JRI Orthopaedics and Zeneca (formerly ICI)
- Chartered Management Accountant

Technologies and  
services to enable the  
delivery of genomic  
medicine



help find the right path to  
improve patient outcomes


# Genomic Technologies      Genomic Services

Target enrichment:  
Ranger® Technology

Precision  
medicine

NIPT

Reproductive  
Health



Research:

- Pharma Programs
- Biomarker discovery
- Clinical trials

Clinical Oncology


Pharmacogenomics /  
Precision medicine

Reproductive  
Health

NGS • PCR • Microarray



# FY22 highlights

- Record revenues of £37.6m, up 105% on the previous year
  - Delivered £3.4m adjusted EBITDA, a £5.4m favourable movement on the previous year
- New facilities completed in Vancouver for scale-up
- Profits from COVID related revenues used to invest in commercial teams across Americas, APAC and EMEA





# FY22 highlights

- **Genomic Services revenues up 240%:**
  - £18.7m from UK-focused COVID PCR testing and variant sequencing services for the DHSC and private sector partners
  - Genomic Services capabilities vastly enhanced compared to pre-pandemic
  
- **Genomic Technologies revenues up 10% excluding COVID**
  - NIPT headwinds in H1 but returned to growth in H2
  - Continued expansion of IONA<sup>®</sup> Nx installed base in USA, Mexico, Singapore and EMEA
  - DPYD test revenues increased to £1.2m for the financial year (FY21: £0.7m) reflecting the wider adoption of this screening test, which is now recommended in Wales, England, Germany, Spain and Belgium





# Segmental performance through pandemic





- **Genomic Services**
  - Revenues +238% driven by COVID services
  - Other services affected by pandemic headwinds, especially in APAC
  - Gross margins of 56% reflect volume / price trade-off with COVID (FY21: 65%)
  - Gross profit contribution used to enhance service capabilities and support Technologies segment
- **Genomic Technologies**
  - Revenues +34% thanks to Clarigene<sup>®</sup>, DPYD and Ranger<sup>®</sup> Technology
  - Non-COVID revenues +9% YoY
  - NIPT: H2 recovery from C19-affected H1
  - Solid contribution from PCR reproductive health range
  - Gross margins held firm at 59% vs 61% despite commodity COVID prices





# 2022 Income Statement





- Revenues +105% driven by COVID services and products
- Gross profits up 88% despite COVID mix dampening margins
- £5.4m favourable EBITDA swing
  - IONA<sup>®</sup> Nx transition completed
  - R&D investment levels maintained at £1.8m pa\*
  - GP increase of £10m required additional direct opex in Genomic Services plus extra support
  - Continuing to expand US presence
  - Other opex includes spending on Ranger<sup>®</sup> Technology capabilities and product management
- Post-period end restructure completed targeting £5m pa reduction in opex: GS retrenchment, consolidation of UK operations and support, rationalised processes

\* net of credits and capitalisations



# 2022 Balance Sheet & Cashflow



- Non-current asset growth solely due to Right of Use Assets (IFRS16)
  - UK facilities overlap as we migrate to single long-term home; will vacate legacy sites within FY23
  - New Vancouver facility for expansion
  - £1.0m impairment of Taiwan Goodwill due to ongoing pandemic challenges
- Liabilities include RoUA associated property leases and Silicon Valley Bank term loan
- Operating cashflows +£3.2m (FY21: -£3.5m) from improved trading
- Working capital net outflow as inventories built for supply chain resilience
- Investing outflow of £3.5m (FY21: -£7.4m) is mainly expansion of Genomic Services for post COVID capabilities & Ranger® Technology
- Financing inflows in FY22 non-dilutive

# Strategic progress post-period end



- Capital Markets Day held in London on 26 April 22 to update institutional and private investors on our growth strategy post-COVID
- Extension of our strategic partnership with Ambry Genetics, part of REALM IDx Inc (formerly Konica Minolta Precision Medicine), with impact later this year:
  - US NIPT launch planned for H2
  - Leading Ambry oncology range added to our UK Genomic Services offering
- Ranger® Technology extended
  - Launch of LightBench® Detect – our clinical platform for DNA target enrichment and its capability to use EDTA blood collection tubes
- NIPT
  - Launch of Microdeletions Plugin Accelerator Phase, as an extension to our NIPT clinical menu
- Operational efficiency review
  - Right sizing restructure completed in Q1 FY23, as part of £5m pa reduction in opex
  - UK site consolidation to be completed in Q2 FY23, enabling sharing of laboratory resources between operations, services and development



# Growth strategy update:

## Ranger® Technology



- Ranger® Technology for targeted enrichment is hugely disruptive to liquid biopsy, RNA and gene synthesis markets
- Launch of LightBench® Detect – clinical platform for liquid biopsy applications such as NIPT and oncology
- Customer Laval University presents at International Society for Prenatal Diagnosis conference and publishes paper showing the utility of Ranger® Technology in EDTA tubes in an NIPT workflow<sup>1</sup>
- Ranger® Technology contracts signed with blue-chip partners including Labcorp and two others
- Lead generation campaign launched which includes:
  - Exhibition attendance at ISPD, Montreal & AACC, Chicago
  - Exhibition attendance at ESHG, Vienna
  - Digital content: white papers, blogs, emails, social media & SEO
  - Distributor training and sales enablement tools

<sup>1</sup>[https://www.jmdjournal.org/article/S1525-1578\(22\)00169-6/fulltext](https://www.jmdjournal.org/article/S1525-1578(22)00169-6/fulltext)



# Growth strategy update:

## NIPT



- Launch of Microdeletions Plugin accelerator phase following a strategic collaboration with Singapore customer LifeStrands
- Significant opportunity to influence and disrupt the NIPT market in the Americas by leveraging our Ranger® Technology for size selection into established competitor NIPT workflows
  - Positioning Yourgene as the *fetal fraction enrichment company* through the utilisation of Ranger® Technology
- Further strengthening commercial teams in EMEA and Americas to capitalise on this opportunity now back to pre-pandemic growth
- 12 customer labs installed in the last 6 months with a Yourgene NIPT workflow
- R&D development programme for the next 12 months which will deliver further competitive advantages for the IONA® Nx workflow to enable the company to win further market share

# Growth strategy update:


## Genomic Services



- Six key growth drivers:
  - Extended clinical NIPT menus including sex chromosome aneuploidies – launch of IONA<sup>®</sup> Care
  - Added new NIPT customers in UK, EMEA and APAC
  - Signed-up new partners for our whole exome sequencing service
  - Addition of partner hypoxic tumour test to oncology menu
  - Increased range of services to existing pharma partners in UK and Taiwan
  - Extension to Ambry Genetics to include partnerships for their oncology portfolio for UK and Ireland:
    - Ambry / Yourgene joint oncology genetics roundtable planned for Autumn and products planned for launch following this
- Expanded scope of accreditations:
  - UKAS accreditation for UK NIPT service
  - Taiwanese LDTS for NIPT in Taipei
  - Started CLIA submission for UK laboratories



# Current Trading & Outlook



- Stable platform from which to deliver future growth across our core portfolio in the market segments which we operate
- Q1 trading returns to pre-pandemic growth rates of +20% year-on-year for core revenue streams (excluding COVID)
- Strategic review of Taiwan laboratory is underway
- Continue to drive adoption of Ranger® Technology in NIPT applications
- Multiple drivers of growth:
  - Diverse Technologies revenue streams built on proprietary technologies with growth opportunities across cell-free DNA applications such as NIPT, oncology, reproductive health and infectious disease
  - Genomic Services: six key growth drivers - continue to transition testing capacity & infrastructure into oncology - enhanced by Ambry Genetics partnership and reproductive health, pharma services



# Board Change

## Dr John Brown CBE – Chairman



*John joined the Yourgene Board as Senior Independent Director in July 2019 and has brought with him a wealth of capital markets experience in the healthcare and life sciences sector*

He has significant experience with previous Board roles at Axis-Shield, BTG, Vectura, Acambis and Acacia Pharma

He was until recently Chairman of the UK's Cell and Gene Therapy Catapult and is currently Chairman of Calcivis Ltd and a NED at Skylark Therapeutics Ltd

John takes the Chair at Yourgene from 27 July 2022



# Yourgene Health – platform for growth



100+ products & services



200 employees



£37.6 million revenue for FY22



Customers in over 65 countries



Operating sites: Manchester - Taipei - Vancouver

Direct commercial presence:

US – Canada - Colombia

Taiwan - Singapore – Thailand – India – Australia

UK - France - Germany

>800,000 patient  
samples tested in  
our labs

>2,250,000  
pregnancies tested

> 4,250,000 tests  
overall

*Diversified income streams with multiple growth drivers,  
a strong Q1 performance and a confident outlook*



# Close



- Thank you to “Investor Meet Company” for hosting the event on their platform
- Any questions that we didn’t have time to answer we will try to answer via the IMC portal

<https://www.investormeetcompany.com/yourgene-health-plc/>

A copy of this presentation and the recording will also be made available on the IMC portal and the Yourgene Health website

<https://www.yourgene-health.com/investors/company-information/investor-presentations>

To be kept up to date with Yourgene Health plc news and to receive relevant investor communications, please email Walbrook PR at [yourgene@walbrookpr.com](mailto:yourgene@walbrookpr.com) to subscribe



# Yourgene Health

[www.yourgene-health.com](http://www.yourgene-health.com)

Yourgene Health Plc  
Citylabs 1.0  
Nelson Street  
Manchester  
M13 9NQ  
United Kingdom

Telephone: +44 (0)161 669 8122  
Email: [investors@yourgene-health.com](mailto:investors@yourgene-health.com)

Lyn Rees  
Chief Executive Officer  
[lyn.rees@yourgene-health.com](mailto:lyn.rees@yourgene-health.com)

Barry Hextall  
Chief Financial Officer  
[barry.hextall@yourgene-health.com](mailto:barry.hextall@yourgene-health.com)